Drugs / [68Ga]Ga-DOTA-STR-17126
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07608848 | May 2026 → May 2028 expected | breast cancer, metastatic prostate carcinoma | Integrated Haematology and Oncology Network | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-STR-17126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07608848 ↗ |
| Action | Inhibit | “GRPR antagonist-based theranostic platform” NCT07608848 ↗ |
| Modality | Diagnostic / imaging agent | “used as a PET imaging tracer” NCT07608848 ↗ |
| Route | Intravenous | “single intravenous bolus dose” NCT07608848 ↗ |
| Target | GRPR | “GRPR-targeted theranostic approach” NCT07608848 ↗ |